SEC Comment Letter for Generation Bio Co. (GBIO) (CIK 0001733294) — May 22, 2020
Generation Bio Co. (GBIO) (CIK 0001733294)
Date: May 22, 2020 · CIK: 0001733294 · Accession: 0000000000-20-004593
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo May 22, 2020 Geoff McDonough, M.D. President and Chief Executive Officer Generation Bio Co. 301 Binney Street Cambridge, MA 02142 Re:Generation Bio Co. Amendment 1 to Draft Registration Statement on Form S-1 Submitted May 12, 2020 CIK No. 0001733294 Dear Dr. McDonough: We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Amendment 1 to Draft Registration Statement Our portfolio, page 3 1.We note your response to our prior comment 3 and your revisions. Please further revise your chart here and at page 113 to include separate columns for each of Phase 1 and Phase 2. Please also adjust your chart to make all labels legible. Use of Proceeds, page 85 2.Please further revise your disclosure in response to prior comment 6 to separately allocate the portion of the proceeds to be allocated to each of the two programs identified in the last sentence on page 85.
FirstName LastNameGeoff McDonough, M.D. Comapany NameGeneration Bio Co. May 22, 2020 Page 2 FirstName LastName Geoff McDonough, M.D. Generation Bio Co. May 22, 2020 Page 2 You may contact Gary Newberry at (202) 551-3761 or Lynn Dicker at (202) 551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Courtney Lindsay at (202) 551-7237 or Mary Beth Breslin at (202) 551-3625 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Molly Fox
Show Raw Text
United States securities and exchange commission logo
May 22, 2020
Geoff McDonough, M.D.
President and Chief Executive Officer
Generation Bio Co.
301 Binney Street
Cambridge, MA 02142
Re:Generation Bio Co.
Amendment 1 to
Draft Registration Statement on Form S-1
Submitted May 12, 2020
CIK No. 0001733294
Dear Dr. McDonough:
We have reviewed your amended draft registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Amendment 1 to Draft Registration Statement
Our portfolio, page 3
1.We note your response to our prior comment 3 and your revisions. Please further revise
your chart here and at page 113 to include separate columns for each of Phase 1 and Phase
2. Please also adjust your chart to make all labels legible.
Use of Proceeds, page 85
2.Please further revise your disclosure in response to prior comment 6 to separately allocate
the portion of the proceeds to be allocated to each of the two programs identified in the
last sentence on page 85.
FirstName LastNameGeoff McDonough, M.D.
Comapany NameGeneration Bio Co.
May 22, 2020 Page 2
FirstName LastName
Geoff McDonough, M.D.
Generation Bio Co.
May 22, 2020
Page 2
You may contact Gary Newberry at (202) 551-3761 or Lynn Dicker at (202) 551-3616 if
you have questions regarding comments on the financial statements and related matters. Please
contact Courtney Lindsay at (202) 551-7237 or Mary Beth Breslin at (202) 551-3625 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Molly Fox